EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Long‐term follow‐up of patients with congenital thrombotic thrombocytopenia purpura receiving a plasma‐derived factor VIII (Koate) that contains ADAMTS13

Tammuella Chrisentery-Singleton, Lisa N Boggio, Manuel D Carcao iD, Sami Ibrahimi, Osman Khan, Arash Mahajerin, Anita Rajasekhar, Vivek Sharma, MacGregor Steele, Marcela Torres, Frank J Rodino, Shannon L Carpenter

Haemophilia · 2023

DOI: 10.1111/hae.14891 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Haemophilia, 2023. Verfasst von Tammuella Chrisentery-Singleton und 11 weiteren Autor:innen. Beteiligte Einrichtung: American Thrombosis and Hemostasis Network, Rochester, New York, USA. Hauptthemen laut MEDLINE: Purpura, Thrombotic Thrombocytopenic, Hemostatics. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Kedrion Biopharma.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Hereditary thrombotic thrombocytopenia purpura (hTTP) is an ultra‐rare disorder resulting from an inherited deficiency of ADAMTS13, a von Willebrand factor (VWF)‐cleaving metalloprotease. The plasma‐derived factor VIII/VWF Koate (FVIII/VWF Koate ) has been shown to contain ADAMTS13, allowing for its use to treat hTTP at home by the patient/caregiver.

Aim

Based on prior demonstration of safe and effective use of FVIII/VWF Koate in eight patients with hTTP, we conducted a retrospective study to gather additional data regarding the use of FVIII/VWF Koate for hTTP.

Methods

This was a multicentre, retrospective, noninterventional chart review of patients who had received FVIII/VWF Koate for the management of hTTP. Data collected included demographics, medical history, relevant family history, past use and tolerability of fresh frozen plasma, and details regarding FVIII/VWF Koate therapy.

Results

The cohort included 11 patients (seven males, four females) with hTTP, ranging in age at study entry from 2 to 28 years. The average duration of FVIII/VWF Koate therapy was 4.8 years (range, 0.5–6.5 years). Among nine patients using FVIII/VWF Koate as prophylaxis, the normalized annual rate of breakthrough TTP episodes ranged from 0.2 to 1.1 episodes/year. All nine patients who received FVIII/VWF Koate prophylaxis had thrombocytopenia recorded at baseline, while eight (88.9%) did not have thrombocytopenia after using FVIII/VWF Koate . There was one AE (unspecified) attributed to FVIII/VWF Koate .

Conclusion

These data suggest that FVIII/VWF Koate is a safe and well‐tolerated source of the missing ADAMTS13 enzyme in patients with hTTP, producing a marked reduction in thrombocytopenia prevalence, low frequency of TTP episodes, and with the added benefit of self‐ or caregiver‐administration.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Purpura, Thrombotic ThrombocytopenicHemostaticsMaleFemaleHumansChild, PreschoolChildAdolescentYoung AdultAdultFactor VIIIvon Willebrand FactorRetrospective StudiesFollow-Up StudiesADAM ProteinsPlasmaADAMTS13 Protein

Stichwörter der Autor:innen

ADAMTS13 proteinUpshaw-Schulman syndromecongenital thrombotic thrombocytopenicfactor VIII/administration and dosagemicroangiopathic haemolytic anaemiapaediatricprophylaxispurpuravon Willebrand factor-cleaving protease

Substanzen

Factor VIIIvon Willebrand FactorADAM ProteinsHemostaticsADAMTS13 ProteinADAMTS13 protein, human

Autor:innen und Institutionen

  • American Thrombosis and Hemostasis Network, Rochester, New York, USA.
  • Ochsner Clinic Foundation, New Orleans, Louisiana, USA.
  • Rush Hemophilia & Thrombophilia Center, Rush University Medical Center, Chicago, Illinois, USA.
  • Division of Haematology/Oncology, Department of Paediatrics, The Hospital for Sick Children, Toronto, ON, Canada.
  • OUHSC/Stephenson Cancer Center, Oklahoma City, Oklahoma, USA.
  • University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, USA.

ORCID-Profile: Manuel D Carcao

Förderung

  • Kedrion Biopharma

Zitieren

APA

Chrisentery-Singleton, T., Boggio, L. N., Carcao, M. D., Ibrahimi, S., Khan, O., Mahajerin, A., Rajasekhar, A., Sharma, V., Steele, M., Torres, M., Rodino, F. J., & Carpenter, S. L. (2023). Long‐term follow‐up of patients with congenital thrombotic thrombocytopenia purpura receiving a plasma‐derived factor VIII (Koate) that contains ADAMTS13. Haemophilia. https://doi.org/10.1111/hae.14891

Vancouver

Chrisentery-Singleton T, Boggio LN, Carcao MD, Ibrahimi S, Khan O, Mahajerin A, et al. Long‐term follow‐up of patients with congenital thrombotic thrombocytopenia purpura receiving a plasma‐derived factor VIII (Koate) that contains ADAMTS13. Haemophilia. 2023. doi:10.1111/hae.14891

BibTeX
@article{ChrisenterySingleton2023,
  author = {Chrisentery-Singleton, Tammuella and Boggio, Lisa N and Carcao, Manuel D and Ibrahimi, Sami and Khan, Osman and Mahajerin, Arash and Rajasekhar, Anita and Sharma, Vivek and Steele, MacGregor and Torres, Marcela and Rodino, Frank J and Carpenter, Shannon L},
  title = {Long‐term follow‐up of patients with congenital thrombotic thrombocytopenia purpura receiving a plasma‐derived factor VIII (Koate) that contains ADAMTS13},
  journal = {Haemophilia},
  year = {2023},
  doi = {10.1111/hae.14891}
}
Kostenlos starten →